By Colin Kellaher

AbbVie Inc.'s Allergan Aesthetics unit on Wednesday said it agreed to buy the dermal-filler portfolio and research-and-development pipeline of Luminera, a privately held Israeli aesthetics company, for an undisclosed amount.

Allergan, which AbbVie acquired earlier this year in a $63 billion deal, said the acquisition enhances its portfolio with the addition of HArmonyCa, a filler intended for facial soft-tissue augmentation that combines hyaluronic acid and calcium hydroxyapatite.

Allergan said HArmonyCa is currently commercially available in Israel and Brazil, and that it will continue to develop the product for the U.S. and other international markets.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-07-20 1018ET